Profile data is unavailable for this security.
About the company
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).
- Revenue in USD (TTM)7.00k
- Net income in USD-21.69m
- Incorporated2019
- Employees18.00
- LocationBenitec Biopharma Inc3940 Trust WayHAYWARD 94545United StatesUSA
- Phone+1 (510) 780-0819
- Fax+1 (302) 636-5454
- Websitehttps://benitec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genelux Corp | 8.00k | -26.54m | 81.85m | 23.00 | -- | 2.14 | -- | 10,231.13 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 82.37m | 12.00 | -- | 8.11 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Cidara Therapeutics Inc | 31.58m | -116.17m | 82.49m | 69.00 | -- | 0.409 | -- | 2.61 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 82.57m | 47.00 | -- | 2.58 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
Medicinova Inc | 1.00m | -8.16m | 82.89m | 13.00 | -- | 1.44 | -- | 82.89 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Ovid Therapeutics Inc | 567.53k | -29.75m | 83.04m | 40.00 | -- | 0.934 | -- | 146.31 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Bioatla Inc | 0.00 | -104.56m | 84.10m | 65.00 | -- | 2.68 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Aclaris Therapeutics Inc | 32.02m | -58.68m | 86.33m | 91.00 | -- | 0.645 | -- | 2.70 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Benitec Biopharma Inc | 7.00k | -21.69m | 86.99m | 18.00 | -- | 2.04 | -- | 12,427.54 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Beyondspring Inc | 1.88m | -15.57m | 89.06m | 35.00 | -- | -- | -- | 47.48 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Hillevax Inc | 0.00 | -156.27m | 90.11m | 90.00 | -- | 0.4353 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
Allovir Inc | 0.00 | -140.34m | 91.14m | 112.00 | -- | 0.7573 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
CytomX Therapeutics Inc | 119.57m | 11.09m | 91.40m | 120.00 | 8.53 | -- | 7.04 | 0.7644 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Karyopharm Therapeutics Inc | 145.67m | -89.91m | 92.15m | 325.00 | -- | -- | -- | 0.6326 | -0.8356 | -0.8356 | 1.17 | -1.06 | 0.5692 | 1.62 | 4.15 | 448,209.20 | -35.14 | -53.02 | -45.50 | -65.85 | 96.04 | 97.18 | -61.72 | -125.15 | 3.56 | -7.37 | 2.00 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 30 Jun 2024 | 1.69m | 16.77% |
Janus Henderson Investors US LLCas of 30 Jun 2024 | 900.82k | 8.93% |
Adage Capital Management LPas of 30 Jun 2024 | 841.40k | 8.34% |
Nantahala Capital Management LLCas of 25 Jul 2024 | 841.40k | 8.34% |
Franklin Advisers, Inc.as of 30 Jun 2024 | 796.64k | 7.90% |
AWM Investment Co., Inc.as of 25 Jul 2024 | 625.00k | 6.20% |
Schonfeld Strategic Advisors LLCas of 30 Jun 2024 | 260.42k | 2.58% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 215.07k | 2.13% |
Geode Capital Management LLCas of 30 Jun 2024 | 63.98k | 0.63% |
Simplify Asset Management, Inc.as of 30 Jun 2024 | 51.22k | 0.51% |